In a significant advancement for digital clinical trials, Medable Inc. has secured approval from France's Commission Nationale de l'Informatique et des Libertés (CNIL) to deploy its electronic consent and clinical outcome assessment solutions across eight countries outside the European Union. This breakthrough positions Medable as a unique data processor operating beyond CNIL MR-001 Reference Methodology requirements for France-based trial sponsors.
The approval process, spanning six months, was achieved through close collaboration with Servier, one of France's largest pharmaceutical companies. The rigorous evaluation required comprehensive platform validation documentation, security demonstrations, and multiple workflow adaptations to meet CNIL's exacting standards.
Strategic Impact on Clinical Research
Dr. Michelle Longmire, CEO and Co-Founder of Medable, emphasized the significance of this development: "This approval is a testament to the strength of our platform and industry collaborations. By combining regulatory expertise, compliance, innovation, and patient-centricity, we're reshaping the future of clinical trials."
The company's software-as-a-service platform has demonstrated remarkable effectiveness across its global operations. Operating in 70 countries and supporting over one million patients, Medable's solutions have achieved notable metrics:
- 90% adherence rate for electronic clinical outcome assessments (eCOA)
- 50% reduction in overall costs
- Potential ROI of $10 million for Phase II trials
- Up to $39 million ROI for Phase III trials with $1.5M investment
Technological Advancement and Market Position
Medable's recent technological initiatives include the launch of Medable AI and Medable Studio, introducing capabilities to instantly convert traditional outcomes assessments into digital eCOAs. These tools are now available through Google Cloud Marketplace, expanding accessibility for research organizations.
The platform's comprehensive deployment statistics underscore its global reach:
- Implementation in nearly 400 clinical trials
- Presence in 70 countries
- Support for 120 languages
- Service to over one million patients worldwide
This CNIL approval represents a crucial step forward in Medable's mission to accelerate therapeutic development through digital innovation. As a venture-backed company based in Palo Alto, California, Medable continues to demonstrate market leadership, recently earning recognition on the Inc. 5000 list for the second consecutive year in 2024.
